We also evaluated the clinical significance of CD73 expression in colorectal cancer patients receiving MAPKi (anti‐EGFR, cetuximab) and demonstrated a significantly worse outcome associated with high CD73 expression. This evidence concerns the gene EGFR and colorectal cancer.